139481-69-9 (2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯,Candesartan Methyl Ester)

CAS号:
139481-69-9
中文名称:
2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯
英文名称:
Candesartan Methyl Ester
分子式:
C25H22N6O3
分子量:
454.480584621429

2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯(139481-69-9)名称与标识符

名称

中文别名:
2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯;坎地沙坦甲酯;2-乙氧基-1-[[(2-(1H-四唑-5-基)甲基]苯并咪唑]-7-羧酸乙酯;2-乙氧基-1-[[(2''-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑;2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸乙酯;3-(乙酰基硫醇)己基醋酸盐;ETHYL 2-ETHOXY-1-[[(2鈥?-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL]BENZIMIDAZOLE]-7-CARBOXYLATE;坎地沙坦酯中间体(甲酯C7) ;坎地沙坦酯中间体C7;坎地沙坦酯中间体甲酯C7;2-乙氧基-1-[[(2`-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸乙酯;坎地沙坦酯中间体C;
英文别名:
Methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate;Candesartan Methyl Ester;Methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate;THYL-2-ETHOXY-1-[[2’-(1HTETRAZOL-5-YL-)METHYL]BENZIMIDAZOLE]-7-CARBOXYLATE,ENTERPRISE STANDARD;Ethyl-2-Ethoxy-1-[[(2'-(1h-Tetrazol-5-Yl)Biphenyl-4-Yl)Methyl]Benzimidazole]-7-Carboxylate;Methyl-2-Ethoxy-1-[[(2'-(1h-Tetrazol-5-Yl)Biphenyl-4-Yl)Methyl]Benzimidazole]-7-Carboxyla;Methyl candesartan;NG25Z8EW4V;Methyl 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate;Methyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)benzimidazole-7-carboxylate;Et;CHEMBL308884;Candesartan-d5MethylEster;Q27284852;Methyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxybenzimidazole-7-carboxylate;Methyl 1-[[2 inverted exclamation mark -(5-Tetrazolyl)-4-biphenylyl]methyl]-2-ethoxybenzimidazole-7-carboxylate;A886000;Methyl 2-ethoxy-1-[[2'-(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate;AKOS015900107;FT-0664227;139481-69-9;CANDESARTAN CILEXETIL IMPURITY I [EP IMPURITY];Methyl 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (Candesartan Methyl Ester);Methyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylate;SCHEMBL1653406;BDBM50044396;CS-0151434;NS00024508;(+/-)-Methyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)benzimidazole-7-carboxylate;methyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]benzimidazole-7-carboxylate;1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, methyl ester;DTXSID60161060;methyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7carboxylate;AKOS016001589;1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, methyl ester;BCP12918;UNII-NG25Z8EW4V;MFCD09263633;D82209;Methyl1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate;2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester;SY269620;DS-12084;Candesartan cilexetil impurity I [EP];methyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate;RBPFEPGTRLLUKI-UHFFFAOYSA-N;MFCD18379253;methyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole-7-carboxylate;Candesartan cilexetil impurity I;methyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl)-1H-benzimidazole-7-carboxylate;CANDESARTAN CILEXETIL IMPURITY I (EP IMPURITY);1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester;DTXCID4083551;

标识符

MDL:
MFCD09263633
InChIKey:
RBPFEPGTRLLUKI-UHFFFAOYSA-N
Inchi:
1S/C25H22N6O3/c1-3-34-25-26-21-10-6-9-20(24(32)33-2)22(21)31(25)15-16-11-13-17(14-12-16)18-7-4-5-8-19(18)23-27-29-30-28-23/h4-14H,3,15H2,1-2H3,(H,27,28,29,30)
SMILES:
O(CC)C1=NC2C=CC=C(C(=O)OC)C=2N1CC1C=CC(C2=CC=CC=C2C2N=NNN=2)=CC=1

2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯(139481-69-9)物化性质

实验特性

  • LogP : 4.50710
  • PSA : 107.81000
  • 折射率 : 1.687
  • 沸点 : 704.488°C at 760 mmHg
  • 熔点 : 169-173°C
  • 闪点 : 379.861°C
  • 颜色与性状 : Powder
  • 密度 : 1.357

计算特性

  • 精确分子量 : 468.19100
  • 氢键供体数量 : 1
  • 氢键受体数量 : 7
  • 可旋转化学键数量 : 8
  • 同位素质量 : 454.17533859g/mol
  • 重原子数量 : 34
  • 复杂度 : 675
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 4.4
  • 拓扑分子极性表面积 : 108

2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯(139481-69-9)安全信息

2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯(139481-69-9)推荐厂家 更多厂家(50)

2-乙氧基-1-[[(2'-(1H-四唑-5-基)联苯-4-基)甲基]苯并咪唑]-7-甲酸甲酯(139481-69-9)参考资料

Reaxys RN:
PubChem CID: